Should I Buy AQST? AQST 2026 Analysis

Should You Buy Aquestive Therapeutics Inc (AQST) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.110

1 Day change

7.03%

52 Week Range

7.550

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: the stock is still in a longer-term downtrend (bearish MA stack) and is sitting just below a key resistance zone (~4.14–4.48), which raises near-term pullback risk.
Event-driven name (FDA CRL + lawsuits): headline flow can whipsaw the price; without Intellectia buy signals today, risk/reward isn’t compelling for “buy-now”.
If you must act today: the only “buy case” is a fast momentum trade on a breakout/hold above ~4.14; otherwise the higher-probability stance is to wait/hold.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Mixed-to-bearish overall. Despite a positive momentum impulse, the moving-average structure is bearish (SMA200 > SMA20 > SMA5), consistent with a broader downtrend/repair phase.
Momentum: MACD histogram +0.117 and expanding supports short-term upside momentum.
RSI (6): 66.7 (upper-neutral) suggests strength but nearing short-term “crowded” levels (not deeply overbought, but not cheap).
Key levels:
- Pivot: 3.577 (near-term line in the sand)
- Resistance: R1 4.135 then R2 4.479 (overhead supply)
- Support: S1 3.019 (air pocket risk if momentum fades)
Pattern-based odds (provided): ~+0.89% next day, +2.06% next week, but -2.84% next month → near-term pop potential, weaker medium-term setup.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Very call-heavy (OI P/C 0.27, Vol P/C 0.18) → options market is bullish/leaning risk-on.
Activity: Today’s volume 684 and volume vs 30-day avg 27.22x → elevated event-driven trading.
Volatility: 30D IV 75.9% vs HV 68% (options pricing in big moves), but IV percentile 20.4 / IV rank 11.2 → IV is relatively low versus its own recent history (options not “peak expensive” compared to prior spikes).
Takeaway: Options flow says traders are betting on upside continuation, but the name remains high-beta around FDA-related headlines.

Technical Summary

Sell

Buy

Positive Catalysts

- FDA CRL characterized as addressable: deficiencies described as limited to packaging/administration & human factors; company targeting parallel HF validation + PK study with potential resubmission by Q3 2026.
- Street leaning constructive post-CRL (multiple Outperform/Buy reiterations), supporting follow-through bids on positive execution updates.
- Near-term momentum: MACD positive and expanding; options positioning is strongly bullish.

Neutral/Negative Catalysts

- Regulatory delay risk: CRL pushes approval/launch timeline out; execution depends on HF testing & PK outcomes and FDA review timing.
- Law-firm investigations (Faruqi & Faruqi, Pomerantz, Schall): typically negative sentiment/headline overhang and can weigh on marginal buyers.
- Technical overhead resistance near 4.14–4.48; failure to clear can trigger fast retracements given the stock’s volatility.
- Medium-term drift risk (provided pattern stats show negative 1-month expectation).

Financial Performance

Latest reported quarter: 2025/Q3
- Revenue: $12.81M, -5.43% YoY (top-line contraction)
- Net income: -$15.45M, +34.21% YoY (loss narrowed meaningfully)
- EPS: -0.14, +7.69% YoY (improving, but still negative)
- Gross margin: 64.82%, -3.60% YoY (some margin pressure)
Read-through: financials show improving losses, but growth is not yet re-accelerating; the stock remains primarily catalyst-driven (FDA pathway for Anaphylm).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Analysts largely reiterated bullish ratings after the FDA CRL, framing it as recoverable/clearing event rather than a fundamental product failure.
Notable calls:
- Oppenheimer (2026-02-02): Outperform, CRL seen as “clearing event,” risk now timeline-driven.
- Leerink (2026-02-02): Outperform, path appears defined; key risk is launch delay and study outcomes.
- Alliance Global (2026-02-02): Buy, $12 PT, believes Q3 2026 resubmission is do-able.
- Piper Sandler (2025-11-07): Overweight, raised PT to $8 (pre-CRL optimism on approval timing).
Wall Street pros: addressable CRL, no major CMC/comparability red flags highlighted, large upside implied by PTs.
Wall Street cons: timeline/execution risk, potential commercial delay, headline/legal overhang.
Influential buying/selling: Hedge funds/insiders reported neutral; no recent congress trading data available.

5 Analyst Rating

Wall Street analysts forecast AQST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AQST is 8.4 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.840

Low

Averages

8.4

High

Current: 3.840

Low

Averages

8.4

High

Lake Street

Buy

downgrade

$8 -> $6

AI Analysis

2026-02-03

New

Reason

Lake Street

Price Target

$8 -> $6

AI Analysis

2026-02-03

New

downgrade

Buy

Reason

Lake Street lowered the firm's price target on Aquestive Therapeutics to $6 from $8 and keeps a Buy rating on the shares after the company announced the receipt of a CRL for Anaphylm and a planned resubmission in Q3. The firm adjusted its revenue estimates accordingly and lowered its price target to account for the delay in the approval of Anaphylm.

Outperform

maintain

2026-02-02

New

Reason

Price Target

2026-02-02

New

maintain

Outperform

Reason

Oppenheimer views the complete response letter from the FDA as a "clearing event" for Aquestive Therapeutics. The letter "provides assurance that the additional work is not related to major concerns to Anaphylm," the analyst tells investors in a research note. The firm views the keys risk going forward as timeline-driven. It keeps an Outperform rating on Aquestive. The stock in morning trading is up 47%, or $1.39, to $4.34.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AQST

Unlock Now

AQST Should I Buy

AQST Should I Buy

Should You Buy Aquestive Therapeutics Inc (AQST) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch